Introduction
India has a population of over one billion people with about 5% being able to afford the very best treatment, 25% in the middle class with increasing income and 70% who cannot afford a transplant unless it is provided by the state, and this is not likely considering other urgent health priorities. 1 With 20 million carriers for thalassemia and 10 000 children being born with thalassemia major each year, if one-third of these patients have an HLA-matched sibling donor, there is a potential to cure 3000 children with BMT. 2 If one considers six per million as the incidence of aplastic anemia, there would be 6000 new cases/year, and if 10% of these patients are suitable candidates for transplant, then the country would need to do 600 transplants per year for this disease alone. India's gross domestic product (GDP) per capita in 1999 was $370 and in 2006, this had risen to $3460 (source: World Population Data Sheet 1999/2006). This means that many patients can now afford to have a transplant even if resources are not available from the state or private insurance.
The process of collecting information and maintaining a database of transplant activity in India has not been streamlined. In September 2005, data were collected from six transplant centers in the country and their location is given in Figure 1 .
HLA typing
The first prerequisite for an allogeneic BMT program is HLA typing: this is available in tertiary hospitals and private laboratories. Serology is still performed for AB (HLA class I typing of AB antigens) typing, but most laboratories use DNA methods for DR (HLA class II typing of DR antigens) typing. The Asian Indian Donor Marrow Registry (AIDMR) is located in New Delhi with a BM database of 3000 donors. High-resolution typing is available at the AIDMR, but only one unrelated transplant using cord blood from the NMDP has been performed so far. There are a few private cord blood banks in India.
Transplant unit
Many hospitals in the West perform transplants in standard single rooms. The much higher level of antimicrobial resistance and poor quality of the environment in developing countries make it prudent to have a dedicated HEPA-filtered transplant unit where there is a high level of control of the environment.
BMT data from India
In September 2005, data were collected from six transplant centers in India and a total of 1540 transplants have been performed in India at these centers (Table 1) . Of these, half were autologous transplants mainly for myeloma. As further national data are not available, the rest of this paper gives data on transplant activity at the Christian Medical College, Vellore. Figure 2 shows the number of transplants performed and the type and Figure 3 indicates the proportion of allogeneic transplants performed for thalassemia in relation to the other diseases. Table 2 gives the distribution of diseases for which a transplant has been performed.
Transplant program at Vellore

Conditioning
For thalassemia, conditioning has been performed with various combinations of BU and CY with or without antilymphocyte globulin. Conditioning for leukemia has been performed with the Tutschka protocol of BU 16 mg/ kg and CY 120 mg/kg. For aplastic anemia, we now use mainly fludarabine-based conditioning 3 and CY TBI is used for ALL. GVHD CYA and short MTX are the main protocol for GVHD with a target CYA level of 250 ng/ml.
Antimicrobial policies
Acyclovir is administered at a dose of 15 mg/kg/day i.v. starting day þ 1, is switched to oral dose after day 14 and is continued for 2-3 months. Most patients and donors are CMV IgG-positive and ganciclovir is started when the CMV-PCR becomes positive post transplant. Trimethoprim sulfa and penicillin are given for 1-year post transplant.
Tuberculosis
Records of 217 BMT patients during the period 1986-1999 were reviewed and mycobacterial infections were diagnosed in three patients, (1.38%), all of whom presented with extrapulmonary disease, and two of these patients had disseminated disease. 4 Infection with Mycobacterium tuberculosis is not a common problem in allogeneic BM recipients even in an endemic area, but when it occurs, it is (Table 3) . However, among the 114 patients who were in class III, there was a 34.4% mortality and 19.4% rejection, which means that these patients should receive better pre-transplant care and should be taken early for BMT. Allogeneic BMT at $15 000-20 000 is equivalent to the cost of 3 years of transfusion and chelation and is a good alternative in the developing world. Allo-SCT in India costs around US$ 15 000-20 000, and this is considerably lower than the cost in the West. It therefore makes sense for the country to develop more transplant centers, and with worldwide medical tourism on the increase, India can (after providing for its own citizens) be on the map for BMT. 7, 8 Data on all transplants at Christian Medical College Hospital, Vellore are being reported to the CIBMTR.
Research activity revolves mainly around pharmacokinetics of BU and CY and conditioning regimens for thalassemia. 9, 10 
